BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Scholar Rock readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Scholar Rock's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07435129-208@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Isembyld (apitegromab): Phase 2 readout est. (NCT07435129)
DESCRIPTION:Isembyld (apitegromab)\, phase 2.\nStudy: Phase 2 Study Evaluat
 ing Apitegromab for the Treatment of FSHD\nEstimated primary completion: J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apitegromab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 35129
URL:https://assetmemo.bio/drug/apitegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-208@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Isembyld (apitegromab): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Isembyld (apitegromab)\, phase 2\, Spinal Muscular Atrophy.\nSt
 udy: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Th
 an 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 pitegromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07047144
URL:https://assetmemo.bio/drug/apitegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
